within delegated powers, limited tender inquires are floated among manufacturers and suppliers registered with the DGS&D. The suppliers are then selected on evaluation of rates offered and acceptability of quality.

(iv) The stores received are subject to pre-test by the Directorate of Quality Assurance. Emergent needs of particular items in small quantities are met by local purchase after following prescribed procedure.

(c) Thousands of items of drugs, medical equipment etc. are procured every year as per requirement in accordance with the procedure set out above by different agencies. This type of information, which will be very voluminious is not being compiled, on a centralised basis..

**Development of vacancies for controlling human fertility**

1729. SHRI SANTOSH BAGRODIA: Will the PRIME MINISTER be pleased to state:

(a) whether the National Institute of Immunology has recently developed vaccines with potential for use in controlling human fertility;

(b) if so, the details thereof;

(c) whether their safety aspects have been properly taken care of; and

(d) whether any of those have been released for clinical trials?

THE MINISTER OF STATE IN THE MINISTRY OF SCIENCE AND TECHNOLOGY AND THE MINISTER OF STATE IN THE DEPARTMENTS OF OCEAN DEVELOPMENT, ATOMIC ENERGY, ELECTRONICS AND SPACE (SHRI K. R. NARAYANAN): (a) and (b) National Institute of Immunology has developed two vaccines with potential for use in controlling human fertility. The HCG vaccine is based on the principle of generation of antibodies against the harmone chorionic gonadotropin thereby preventing the implantation of the ovum in the womb. If successful and approved, this vaccine would be for use in women for prevention of pregnancy. The LHRH vaccine is based on the principle of generation of antibodies against the hormone Leutinizing Hormone Releasing Hormone and can be used in both males and females.

(c) and (d). The safety aspect of both the HCG vaccine and the LHRH vaccine has been investigated according to the protocols drawn by the Expert Committee of the Indian Council of Medical Research. Phase I clinical trials for the HCG vaccine has been completed. In respect of the LHRH vaccine clearance has been sought from the Drug Controller of India for conducting the Phase I clinical trials.

**Opening of a New CGHS dispensary**

1730. SHRI SOHAN LAL DHUSIYA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state what are the financial implications for opening a New Central Government Health Scheme Dispensary for each system of medicine, stating the details regarding supply of man-power and medicines, separately system-wise?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): Information is being collected and will be laid on the Table of House.

**मेडिकल कालेजों में दाखिला**

1731. **श्री सत्य प्रकाश मालवीय :** क्या **स्वास्थ्य और परिवार कल्याण** मंत्री यह बताने की कृपा करेंगे कि :

(क) देश में केन्द्रीय सरकार के मेडिकल कालेजों में प्रतिवर्ष कुल कितने उम्मीदवार दाखिल किए जाते हैं; और

(ख) इन कालेजों में आरक्षित स्थानों की संख्या तथा अन्य ब्यौरा क्या है ?

**स्वास्थ्य और परिवार कल्याण मंत्रालय में राज्य मंत्री (कुमारी सरोज खापर्डे) :** (क) और (ख) संस्थाओं, जिनसे केन्द्र सरकार का सीधा संबंध है, से संबंधित सूचना इस प्रकार है :—